PE20200722A1 - Metodos de terapia genica del factor viii (fviii) - Google Patents
Metodos de terapia genica del factor viii (fviii)Info
- Publication number
- PE20200722A1 PE20200722A1 PE2020000180A PE2020000180A PE20200722A1 PE 20200722 A1 PE20200722 A1 PE 20200722A1 PE 2020000180 A PE2020000180 A PE 2020000180A PE 2020000180 A PE2020000180 A PE 2020000180A PE 20200722 A1 PE20200722 A1 PE 20200722A1
- Authority
- PE
- Peru
- Prior art keywords
- nucleic acid
- fviii
- factor viii
- methods
- gene therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762540053P | 2017-08-01 | 2017-08-01 | |
| US201762583890P | 2017-11-09 | 2017-11-09 | |
| US201762596670P | 2017-12-08 | 2017-12-08 | |
| US201762596535P | 2017-12-08 | 2017-12-08 | |
| PCT/US2018/044892 WO2019028192A1 (en) | 2017-08-01 | 2018-08-01 | METHODS OF GENE THERAPY TARGETING FACTOR VIII (FVIII) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20200722A1 true PE20200722A1 (es) | 2020-07-21 |
Family
ID=65234171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000180A PE20200722A1 (es) | 2017-08-01 | 2018-08-01 | Metodos de terapia genica del factor viii (fviii) |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200237930A1 (OSRAM) |
| EP (1) | EP3661541A4 (OSRAM) |
| JP (1) | JP7499174B2 (OSRAM) |
| KR (2) | KR20200066289A (OSRAM) |
| CN (1) | CN111163796A (OSRAM) |
| AU (2) | AU2018312565A1 (OSRAM) |
| BR (1) | BR112020001979A2 (OSRAM) |
| CA (1) | CA3071519A1 (OSRAM) |
| CL (1) | CL2020000295A1 (OSRAM) |
| CO (1) | CO2020002283A2 (OSRAM) |
| IL (1) | IL272373A (OSRAM) |
| MX (1) | MX2020001402A (OSRAM) |
| MY (1) | MY208862A (OSRAM) |
| PE (1) | PE20200722A1 (OSRAM) |
| PH (1) | PH12020500239A1 (OSRAM) |
| SG (1) | SG11202000650YA (OSRAM) |
| WO (1) | WO2019028192A1 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| PE20231949A1 (es) | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| KR102592176B1 (ko) | 2018-01-05 | 2023-10-20 | 플레이틀렛 바이오제네시스, 인크. | 거핵구 생성을 위한 조성물 및 방법 |
| WO2020006539A1 (en) | 2018-06-29 | 2020-01-02 | Platelet Biogenesis, Inc. | Compositions for drug delivery and methods of use thereof |
| MX2021001375A (es) * | 2018-08-03 | 2021-04-19 | Sangamo Therapeutics Inc | Parametros clinicos mejorados por la expresion del factor viii. |
| MA54951A (fr) | 2019-02-15 | 2021-12-22 | Bayer Healthcare Llc | Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée |
| MA55313A (fr) | 2019-03-13 | 2022-01-19 | Generation Bio Co | Vecteurs d'adn non viraux et leurs utilisations pour exprimer des agents thérapeutiques du facteur viii |
| CN110684798A (zh) * | 2019-09-03 | 2020-01-14 | 深圳新诺微环生物科技有限公司 | 肌肉靶向的微环dna基因治疗 |
| WO2021084277A2 (en) * | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Transcription regulatory elements |
| US20220403005A1 (en) * | 2019-12-06 | 2022-12-22 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
| CN114989307B (zh) * | 2022-05-11 | 2023-08-01 | 华兰生物工程股份有限公司 | 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法 |
| CN115948408A (zh) * | 2022-09-23 | 2023-04-11 | 上海信致医药科技有限公司 | 改进的人凝血因子viii基因表达盒及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6818439B1 (en) * | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| CA2387484A1 (en) * | 1999-10-12 | 2001-04-19 | Haim Burstein | Adeno-associated virus vectors encoding factor viii and methods of using the same |
| SI3044231T1 (sl) * | 2013-09-12 | 2020-12-31 | Biomarin Pharmaceutical Inc. | Vektorji AAV, ki vsebujejo gen, ki kodira faktor VIII |
| CA3237630A1 (en) * | 2014-08-13 | 2016-02-18 | The Children's Hospital Of Philadelphia | An improved expression cassette for packaging and expression of variant factor viii for the treatment of hemostasis disorders |
| ES3009565T3 (en) * | 2015-04-16 | 2025-03-27 | Univ Emory | Recombinant promoters and vectors for protein expression in liver and use thereof |
| RU2020126034A (ru) * | 2015-09-24 | 2020-09-02 | Байомарин Фармасьютикал Инк. | Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции |
| EP3368664A4 (en) * | 2015-10-28 | 2019-08-28 | Sangamo Therapeutics, Inc. | LIFE-SPECIFIC CONSTRUCTS, FACTOR VIII EXPRESSION CASSETTES AND METHOD OF USE THEREOF |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| WO2017123961A1 (en) * | 2016-01-14 | 2017-07-20 | The Children's Hospital Of Philadelphia | Factor viii variants, nucleic acid sequences, and methods and uses for treatment of hemostasis disorders |
-
2018
- 2018-08-01 MY MYPI2020000557A patent/MY208862A/en unknown
- 2018-08-01 CA CA3071519A patent/CA3071519A1/en active Pending
- 2018-08-01 CN CN201880064058.9A patent/CN111163796A/zh active Pending
- 2018-08-01 MX MX2020001402A patent/MX2020001402A/es unknown
- 2018-08-01 BR BR112020001979-8A patent/BR112020001979A2/pt unknown
- 2018-08-01 WO PCT/US2018/044892 patent/WO2019028192A1/en not_active Ceased
- 2018-08-01 EP EP18840279.6A patent/EP3661541A4/en active Pending
- 2018-08-01 KR KR1020207005859A patent/KR20200066289A/ko not_active Ceased
- 2018-08-01 AU AU2018312565A patent/AU2018312565A1/en not_active Abandoned
- 2018-08-01 JP JP2020505478A patent/JP7499174B2/ja active Active
- 2018-08-01 KR KR1020247034886A patent/KR20240160648A/ko active Pending
- 2018-08-01 US US16/635,957 patent/US20200237930A1/en not_active Abandoned
- 2018-08-01 SG SG11202000650YA patent/SG11202000650YA/en unknown
- 2018-08-01 PE PE2020000180A patent/PE20200722A1/es unknown
-
2020
- 2020-01-30 IL IL272373A patent/IL272373A/en unknown
- 2020-01-31 CL CL2020000295A patent/CL2020000295A1/es unknown
- 2020-01-31 PH PH12020500239A patent/PH12020500239A1/en unknown
- 2020-02-28 CO CONC2020/0002283A patent/CO2020002283A2/es unknown
-
2024
- 2024-09-03 AU AU2024219336A patent/AU2024219336A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12020500239A1 (en) | 2021-01-11 |
| BR112020001979A2 (pt) | 2020-08-18 |
| KR20200066289A (ko) | 2020-06-09 |
| CA3071519A1 (en) | 2019-02-07 |
| EP3661541A1 (en) | 2020-06-10 |
| MX2020001402A (es) | 2021-01-29 |
| WO2019028192A1 (en) | 2019-02-07 |
| IL272373A (en) | 2020-03-31 |
| CL2020000295A1 (es) | 2020-12-04 |
| AU2018312565A1 (en) | 2020-02-27 |
| MY208862A (en) | 2025-06-04 |
| KR20240160648A (ko) | 2024-11-11 |
| JP7499174B2 (ja) | 2024-06-13 |
| RU2020108209A (ru) | 2021-09-02 |
| JP2020533276A (ja) | 2020-11-19 |
| EP3661541A4 (en) | 2021-09-01 |
| AU2024219336A1 (en) | 2024-09-19 |
| SG11202000650YA (en) | 2020-02-27 |
| CO2020002283A2 (es) | 2020-04-24 |
| US20200237930A1 (en) | 2020-07-30 |
| CN111163796A (zh) | 2020-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20200722A1 (es) | Metodos de terapia genica del factor viii (fviii) | |
| UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
| MY190926A (en) | Cpg reduced factor viii variants, compositions and methods and uses for treatment of hemostasis disorders | |
| CL2019002474A1 (es) | Vector clado f de virus adeno-asociado (vaa) y usos relacionados. | |
| BR112018006074A2 (pt) | vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas | |
| EA202190827A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
| CO2021000914A2 (es) | Productos y métodos de virus adenoasociado recombinante para el tratamiento de la distrofia muscular de cinturas 2a | |
| MX2017014532A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| MX2022005236A (es) | Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina. | |
| BR112021026439A2 (pt) | Vacina para febre suína africana | |
| MX2021009696A (es) | Vectores de genoterapia para el tratamiento de la enfermedad de danon. | |
| MX2019006515A (es) | Composiciones que comprenden peptido wkdeagkplvk. | |
| MX2019012452A (es) | Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
| EA202092049A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
| ZA202202180B (en) | Engineered hcv e2 immunogens and related vaccine compositions | |
| EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
| PH12018500468A1 (en) | Fusion protein | |
| PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
| PE20190104A1 (es) | Antigenos y anticuerpos de chagas y composiciones, metodos y usos de los mismos | |
| AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes | |
| AR109167A1 (es) | Aumento de la fertilidad en especies bovinas | |
| EP4265271A3 (en) | Vaccine immunogens | |
| AR120362A1 (es) | Composiciones y métodos para el tratamiento de la pérdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina |